Shenzhen Kangtai Biological Products Co., Ltd.

XSEC:300601 Stock Report

Market Cap: CN¥16.3b

Shenzhen Kangtai Biological Products Past Earnings Performance

Past criteria checks 3/6

Shenzhen Kangtai Biological Products's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 10.6% per year. Shenzhen Kangtai Biological Products's return on equity is 5.3%, and it has net margins of 17%.

Key information

-6.3%

Earnings growth rate

-8.1%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate10.6%
Return on equity5.3%
Net Margin17.0%
Next Earnings Update21 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shenzhen Kangtai Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300601 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,0315151,415454
30 Jun 242,9495161,391476
31 Mar 243,1817101,439524
31 Dec 233,4778611,518501
30 Sep 233,0573611,312579
30 Jun 233,0602571,332707
31 Mar 233,034-2011,326791
01 Jan 233,157-1331,355802
30 Sep 223,8404301,272713
30 Jun 224,4281,0471,135569
31 Mar 224,2471,5121,013384
01 Jan 223,6521,263830354
30 Sep 213,2181,282992347
30 Jun 212,4437561,061307
31 Mar 212,3617021,097299
31 Dec 202,2616791,050267
30 Sep 201,9695771,002215
30 Jun 202,0065761,012212
31 Mar 201,779477904206
31 Dec 191,943575948198
30 Sep 191,911490978219
30 Jun 191,761407944201
31 Mar 191,9554261,102190
31 Dec 182,0174361,156178
30 Sep 181,8674351,070118
30 Jun 181,756431963133
31 Mar 181,418296832100
31 Dec 171,16121570885
30 Sep 171,00616865151
30 Jun 178161015820
31 Mar 17552523970
31 Dec 16552863420
30 Sep 16460863780
31 Dec 15453632110
31 Dec 14303311450

Quality Earnings: 300601 has a large one-off gain of CN¥154.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300601's current net profit margins (17%) are higher than last year (11.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300601's earnings have declined by 6.3% per year over the past 5 years.

Accelerating Growth: 300601's earnings growth over the past year (42.7%) exceeds its 5-year average (-6.3% per year).

Earnings vs Industry: 300601 earnings growth over the past year (42.7%) exceeded the Biotechs industry 1.3%.

Return on Equity

High ROE: 300601's Return on Equity (5.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 03:32
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Kangtai Biological Products Co., Ltd. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Diandian LiChina Merchants Securities Co. Ltd.
Bing ZhaoChina Renaissance Securities